<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">Tumors of female reproductive system</journal-id><journal-title-group><journal-title xml:lang="en">Tumors of female reproductive system</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли женской репродуктивной системы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1994-4098</issn><issn publication-format="electronic">1999-8627</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">631</article-id><article-id pub-id-type="doi">10.17650/1994-4098-2019-15-1-35-41</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>GYNECOLOGY. ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ГИНЕКОЛОГИЯ. ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Chemoembolization with HepaSpheres in the treatment of recurrent pelvic tumors</article-title><trans-title-group xml:lang="ru"><trans-title>Химиоэмболизация с помощью гепасфер в лечении больных с рецидивными опухолями малого таза</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1031-9376</contrib-id><name-alternatives><name xml:lang="en"><surname>Kedrova</surname><given-names>A. G.</given-names></name><name xml:lang="ru"><surname>Кедрова</surname><given-names>А. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Obstetrics and Gynecology, Academy of Postgraduate Education, Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical and Biological Agency of the Russian FederationFe</p><p><italic>28 Orekhovyy Boulevard, Moscow 115682,</italic></p><p><italic>91 Volokolamskoe  Shosse, Moscow 125371</italic><italic/></p></bio><bio xml:lang="ru"><p><bold>Анна Генриховна Кедрова</bold></p><p>Кафедра акушерства и гинекологии, Академия постдипломного образования ФГБУ ФНКЦ ФМБА России</p><p><italic>115682 Москва, Ореховый бульвар, 28, </italic></p><p><italic>125371 Москва, Волоколамское шоссе, 91</italic></p></bio><email>kedrova.anna@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lebedev</surname><given-names>D. P.</given-names></name><name xml:lang="ru"><surname>Лебедев</surname><given-names>Д. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p> </p><p><italic>28 Orekhovyy Boulevard, Moscow 115682</italic></p></bio><bio xml:lang="ru"><p><italic>115682 Москва, Ореховый бульвар, 28</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zvezdkina</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Звездкина</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p> </p><p><italic>28 Orekhovyy Boulevard, Moscow 115682</italic></p></bio><bio xml:lang="ru"><p><italic>115682 Москва, Ореховый бульвар, 28</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Astakhov</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Астахов</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p> </p><p><italic>28 Orekhovyy Boulevard, Moscow 115682</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kosyy</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Косый</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p> </p><p><italic>28 Orekhovyy Boulevard, Moscow 115682</italic></p></bio><bio xml:lang="ru"><p><italic>115682 Москва, Ореховый бульвар, 28</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ishchenko</surname><given-names>R. V.</given-names></name><name xml:lang="ru"><surname>Ищенко</surname><given-names>Р. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Surgery</p><p><italic>28 Orekhovyy Boulevard, Moscow 115682</italic></p></bio><bio xml:lang="ru"><p>Кафедра хирургии, Академии постдипломного образования ФГБУ ФНКЦ ФМБА России</p><p><italic>115682 Москва, Ореховый бульвар, 28</italic></p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical and Biological Agency of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства России» (ФНКЦ ФМБА России)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Academy of Postgraduate Education, Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical and Biological Agency of the Russian Federation</institution></aff><aff><institution xml:lang="ru">Академия постдипломного образования ФГБУ ФНКЦ ФМБА России</institution></aff></aff-alternatives><content-language>ru</content-language><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2019-07-01"><day>01</day><month>07</month><year>2019</year></pub-date><pub-date date-type="collection"><year>2019</year></pub-date><volume>15</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>35</fpage><lpage>41</lpage><history><date date-type="received" iso-8601-date="2019-07-01"><day>01</day><month>07</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-07-01"><day>01</day><month>07</month><year>2019</year></date></history><pub-history><event event-type="received"><event-desc>Received:<date date-type="received" iso-8601-date="2019-07-01"><day>01</day><month>07</month><year>2019</year></date></event-desc></event><event event-type="accepted"><event-desc>Accepted:<date date-type="accepted" iso-8601-date="2019-07-01"><day>01</day><month>07</month><year>2019</year></date></event-desc></event><event event-type="pub"><event-desc>Published:<pub-date date-type="pub" publication-format="electronic" iso-8601-date="2019-07-01"><day>01</day><month>07</month><year>2019</year></pub-date></event-desc></event></pub-history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ojrs.abvpress.ru/ojrs/article/view/631">https://ojrs.abvpress.ru/ojrs/article/view/631</self-uri><abstract xml:lang="en"><p>Transarterial chemoembolization of the main vessels feeding the tumor is a minimally invasive procedure, which is intended to block off the blood supply to the tumor and to deliver a cytotoxic agent to tumor cells. Initially, this method was used in emergency cases, but later it gained the trust of clinicians, who began to use it in non-emergency patients with clinical manifestations, when angiography showed well-supplied tumors inaccessible for ablation or surgical removal, including those in non-standard difficult cases. Selective catheterization of dominant arteries in recurrent tumors along with chemoembolization with drug-eluting microspheres is extremely challenging, since most of recurrent tumors have a well-developed neovascular network. HepaSphere microspheres, due to their hydrophilicity and high biological compatibility with tissues, allow the deposition of a chemotherapeutic agent in the tumor. This therapy provides pronounced hemostatic and antitumor effects confirmed by morphological and immunohistochemical examination. Currently, transarterial chemoembolization is mainly used for primary tumors and becomes increasingly popular as an element of combination therapy for patients with pelvic tumors. In this article, we analyze clinical data for 14 patients with recurrent pelvic tumors who underwent chemoembolization with HepaSpheres loaded with doxorubicin or irinotecan as a part of their palliative care.</p></abstract><trans-abstract xml:lang="ru"><p>Метод трансартериальной химиоэмболизации доминантных артерий опухоли – минимально инвазивная процедура, выполняемая в интервенционной радиологии для остановки кровоснабжения опухоли с непосредственным цитотоксическим действием – изначально применялся в чрезвычайных ситуациях, но с течением времени завоевал доверие клиницистов и стал использоваться планово у клинически симптомных больных, когда при ангиографии выявляются хорошо кровоснабжающиеся опухоли, малодоступные для аблации или хирургического удаления, в том числе и в нестандартных ситуациях лечения сложных пациентов. Селективная катетеризация доминантных артерий рецидивных опухолей с химиоэмболизацией лекарственно-насыщаемыми микросферами – крайне сложная задача, так как в большинстве случаев рецидивные опухоли имеют очень мелкую разветвленную сеть сосудов, расположенных без первичной анатомии. Микросферы HepaSphere за счет своей гидрофильности и биологической совместимости с тканями позволяют депонировать химиопрепарат в самой опухоли и достигать длительного лекарственного действия на нее. В итоге выраженные гемостатический и противоопухолевый эффекты подтверждаются морфологическим и иммуногистохимическим исследованиями. Сегодня трансартериальная химиоэмболизация чаще применяется при лечении первичных опухолей, все больше завоевывая нишу в комплексной терапии пациенток с опухолями таза. В статье приводится анализ данных 14 больных с рецидивными опухолями, локализованными в области таза, у которых химиоэмболизация гепасферами, насыщенными доксорубицином или иринотеканом, проводилась как метод паллиативной спасительной терапии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>arterial chemoembolization</kwd><kwd>recurrent pelvic tumors</kwd><kwd>bleeding from recurrent pelvic tumors</kwd><kwd>HepaSphere</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>артериальная химиоэмболизация</kwd><kwd>рецидивы опухолей в малом тазу</kwd><kwd>кровотечение из рецидивной опухоли таза</kwd><kwd>HepaSphere</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>De Foucher T., Bendifallah S., Ouldamer L. et al. Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group. Eur J Surg Oncol 2019;45(4):659–65. DOI: 10.1016/j.ejso.2018.11.014.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Lee N., Kim S.I., Lee M. et.al. Bevacizumab efficacy and recurrence pattern of persistent and metastatic cervical cancer. In Vivo 2019;33(3):863–8. DOI: 10.21873/invivo.11551.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Pfaendler K.S., Tewari K.S. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 2016; 214(1):22–30. DOI: 10.1016/j.ajog.2015.07.022.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Bandyopadhyay A., Mukherjee U., Ghosh S. et al. Pattern of failure with locally advanced cervical cancer – a retrospective audit and analysis of contributory factors. Asian Pac J Cancer Prev 2018;19(1):73–9. DOI: 10.22034/APJCP.2018.19.1.73.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Moore D.H., Blessing J.A., McQuellon R.P. et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22(15):3113–9. DOI: 10.1200/JCO.2004.04.170.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Monk B.J., Sill M.W., McMeekin D.S. et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2009;27(28):4649–55. DOI: 10.1200/JCO.2009.21.8909.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Heaston D.K., Mineau D.E., Brown B.J. et al. Transcatheter arterial embolization for control of persistent massive puerperal hemorrhage after bilateral surgical hypogastric artery ligation. AJR Am J Roentgenol 1979;33:152–4.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Wang H.X., Li S.H., Zhao H.Y. Effect of different preoperative neoadjuvant chemotherapy on cervical cancer angiogenesis and cell proliferation. Journal of Hainan Medical University 2016;22(20):115–8.</mixed-citation></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Instruction for loading cytostatic agents into the HepaSphere microspheres. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Инструкции по загрузке цитостатиков в HepaSphere.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><mixed-citation>Tinelli A., Prudenzano R., Malvasi A. et al. Emergency endovascular nanopharmacologic treatment in advanced gynecological cancers. Int J Gynecol Cancer 2010;20:1250–5.</mixed-citation></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Kedrova A.G., Lebedev D.P., Shablovskiy O.R. et al. Chemoembolization of pelvic vessels as a stage of treatment for cervical and uterine cancer. Klinicheskaya praktika = Clinical practice 2016;2:50–6. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Кедрова А.Г., Лебедев Д.П., Шабловский О.Р. и др. Современная химиоэмболизация сосудов малого таза как этап лечения злокачественных опухолей шейки и тела матки. Клиническая практика 2016;2:50–6.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>Yin Y.J., Li H.Q., Sheng X.G. et al. The treatment of pelvic locoregional recurrence of cervical cancer after radical surgery with intensity-modulated radiation therapy compared with conventional radiotherapy: a retrospective study. Int J Gynecol Cancer 2015;25(6):1058–65.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Usuki N., Hirokawa K., Tashiro T. et al. Intraarterial chemotherapy for uterine cervical adenocarcinoma: evaluation of its efficacy as neoadjuvant therapy. Nihon Igaku Hoshasen Gakkai Zasshi 1999;59(12):670–3.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Tsubamoto H., Wada R., Kanazawa R. et al. Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma. J Clin Oncol 2009;27(suppl):e16518. DOI: 10.1200/jco.2009.27.15_suppl.e16518.</mixed-citation></ref></ref-list></back></article>
